ArticlePloS one2013
Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- The relationship between adipose tissue RAAS activity and the risk factors of prediabetes: a systematic review and meta-analysis.Adipocyte · 2023Pooled it
- Pooled it
- Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.Metabolism: clinical and experimental · 2014Trial
- Association Between Different Antiretroviral Therapy Regimens and Adipokine Secretion Profile in HIV-Infected Individuals.International journal of molecular sciences · 2026Article
- Circulating Adiponectin and Omentin Across Cardiometabolic Phenotypes: Links to Atherogenic Indices in Prediabetes and New-Onset Type 2 Diabetes.International journal of molecular sciences · 2026Article
- Circulating fibroblast growth factor-21, Omentin-1, and betatrophin and their association with metabolic parameters in Saudi adolescents post 12-month lifestyle change program.BMC pediatrics · 2025Article
- Therapeutic potential of omentin-1 in preeclampsia: enhancing fetal outcomes, vascular function, and reducing inflammation.Experimental animals · 2025Article
- Exploring Holy Basil's Bioactive Compounds for T2DM Treatment: Docking and Molecular Dynamics Simulations with Human Omentin-1.Cell biochemistry and biophysics · 2025Article
- Omentin: A Key Player in Glucose Homeostasis, Atheroprotection, and Anti-Inflammatory Potential for Cardiovascular Health in Obesity and Diabetes.Biomedicines · 2024Review
- The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.Journal of translational medicine · 2023Article
- State of art on the mechanisms of laparoscopic sleeve gastrectomy in treating type 2 diabetes mellitus.World journal of diabetes · 2023Review
- Regulation of cardiovascular health and disease by visceral adipose tissue-derived metabolic hormones.The Journal of physiology · 2023Article
- Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- Omentin-1 Levels and Outcomes in Incident Peritoneal Dialysis Patients.Kidney medicine · 2023Article
- Fat-to-heart crosstalk in health and disease.Frontiers in genetics · 2023Review
- Article
- Characterization of an intelectin-1 (Frontiers in immunology · 2022Article
- Can epicardial and pericardial adipose tissue volume predict the presence and severity of coronary artery disease?Polish journal of radiology · 2022Article
- Circulating adiponectin mediates the association between omentin gene polymorphism and cardiometabolic health in Asian Indians.PloS one · 2021Article
- Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity.American journal of cardiovascular disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAdipokines are linked to the development of cardiovascular dysfunction in type 2 diabetes (DM2). In DM2-patients, circulating levels of omentin-1, an adipokine preferentially expressed in epicardial adipose tissue, are decreased. This study investigated whether omentin-1 has a cardioprotective function.
methodsOmentin-1 levels in plasma and cardiac fat depots were determined in DM2-patients versus controls. Moreover, the relation between omentin-1 levels and cardiac function was examined in men with uncomplicated DM2. Finally, we determined whether omentin-1 could reverse the induction of cardiomyocyte dysfunction by conditioned media derived from epicardial adipose tissue from patients with DM2.
resultsOmentin-1 was highly expressed and secreted by epicardial adipose tissue, and reduced in DM2. Circulating omentin-1 levels were lower in DM2 versus controls, and positively correlated with the diastolic parameters early peak filling rate, early deceleration peak and early deceleration mean (all P<0.05). The improved diastolic function following pioglitazone treatment associated with increases in omentin-1 levels (P<0.05). In vitro, exposure of cardiomyocytes to conditioned media derived from epicardial adipose tissue from patients with DM2 induced contractile dysfunction and insulin resistance, which was prevented by the addition of recombinant omentin.
conclusionThese data identify omentin-1 as a cardioprotective adipokine, and indicate that decreases in omentin-1 levels could contribute to the induction of cardiovascular dysfunction in DM2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.